Working… Menu

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00826540
Recruitment Status : Completed
First Posted : January 22, 2009
Results First Posted : March 3, 2014
Last Update Posted : September 6, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology

Brief Summary:
This phase II trial is studying how well giving sorafenib together with bevacizumab works in treating patients with metastatic colorectal cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Sorafenib and bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with bevacizumab may kill more tumor cells

Condition or disease Intervention/treatment Phase
Recurrent Colon Cancer Recurrent Rectal Cancer Stage IV Colon Cancer Stage IV Rectal Cancer Drug: sorafenib tosylate Biological: bevacizumab Phase 2

Detailed Description:


I. Evaluate proportion of patients who are progression-free at 3 months (in historic comparison with results for single-agent bevacizumab in ECOG 3200).


I. Response rate (RR) II. Overall survival (OS) III. Safety IV. Feasibility

OUTLINE: This is a multicenter study.

Patients receive sorafenib tosylate orally twice daily on days 1-5 and 8-12 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and then periodically during study treatment for laboratory biomarker and pharmacogenetic studies.

After completion of study treatment, patients are followed periodically for up to 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 83 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Actual Study Start Date : September 2009
Actual Primary Completion Date : January 2010
Actual Study Completion Date : February 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment (sorafenib tosylate and bevacizumab)
Patients receive sorafenib tosylate orally twice daily on days 1-5 and 8-12 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and then periodically during study treatment for laboratory biomarker and pharmacogenetic studies
Drug: sorafenib tosylate
Given orally
Other Names:
  • BAY 43-9006
  • BAY 43-9006 Tosylate Salt
  • BAY 54-9085
  • Nexavar
  • SFN

Biological: bevacizumab
Given IV
Other Names:
  • anti-VEGF humanized monoclonal antibody
  • anti-VEGF monoclonal antibody
  • Avastin
  • rhuMAb VEGF

Primary Outcome Measures :
  1. Progression-free Survival Rate [ Time Frame: At 3 months ]

    The primary endpoint of this trial is progression free survival at 3 months. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be considered evaluable. Patients lost to follow-up before 3 months (e.g., progression, refusing further treatment, etc.) will be considered treatment failures. All eligible patients will be followed until death or a minimum of 3 years. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients.

    Progression is defined as at least a 20% increase in the sum of longest liameter of target lesions taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.

Secondary Outcome Measures :
  1. Response Rate [ Time Frame: Up to 2 years ]
    Simple frequency analysis will be conducted to see if response rate is related to prior treatment and the selected tumor biomarkers. Descriptive statistics will be used to investigate how prior treatment affects various other measures as well.

  2. Overall Survival [ Time Frame: Time from registration to death, assessed up to 2 years ]
    The distribution of overall survival will be estimated using Kaplan-Meier methodology.

  3. Feasibility of Study Treatment [ Time Frame: Up to 2 years ]

    Will be evaluated based on the number of patients who are able to

    > tolerate the regimen, how long they tolerate it and whether they elect to stop treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of stage IV colorectal cancer (histologic proof is not required)
  • Measurable disease

    • Spiral CT scan required for both pre- and post-treatment tumor assessments of lesions measuring 1-2 cm
  • Progressive disease during or within 6 months of most recent prior chemotherapy regimen (bevacizumab, fluoropyrimidine, oxaliplatin, or irinotecan-based treatment) OR considered ineligible for standard therapy
  • Documentation of submission of tumor material for Kirsten Rat Sarcoma (KRAS) testing available
  • Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (e.g., cetuximab or panitumumab) required for patients with wild-type KRAS tumor
  • No known brain metastasis

    • Patients with neurological symptoms must undergo a CT scan or MRI of the brain to exclude brain metastasis
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Life expectancy ≥ 6 months
  • Hemoglobin ≥ 9.0 g/dL
  • Absolute neutrophil count (ANC) ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • White blood cell count (WBC) ≥ 3,400/mm³
  • International normalized ratio (INR) < 1.5 (≤ 3.0 if on anti-coagulation therapy [e.g., warfarin or heparin])
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) ≤ 2.5 times ULN (≤ 5 times ULN if there is liver involvement)
  • Alkaline phosphatase ≤ 3 times ULN
  • Creatinine ≤ 1.5 times ULN
  • Urine protein:creatinine ratio < 1 OR urine dipstick < 2+ OR urine protein < 1,000 mg by 24-hour urine collection
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment (≥ 2 weeks after completion of treatment with sorafenib tosylate alone)
  • Willing to provide mandatory blood samples for translational research studies
  • Able to swallow whole pills
  • No inadequately controlled hypertension (i.e., systolic BP > 150 mm Hg or diastolic BP > 100 mm Hg on anti-hypertensive medications)
  • No prior hypertensive crisis or hypertensive encephalopathy
  • No myocardial infarction or unstable angina within the past 6 months
  • No congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
  • No thrombolic or embolic events (e.g., cerebrovascular accident, including transient ischemic attacks) within the past 6 months
  • No hemorrhage or bleeding event > grade 3 within the past 4 weeks
  • No evidence or history of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)
  • No greater than normal risk of bleeding
  • No active or recent hemoptysis (≥ ½ teaspoon of bright red blood per episode) within the past 30 days
  • No concurrent uncontrolled illness including, but not limited to, any of the following:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia requiring anti-arrhythmic drugs
    • Psychiatric illness or social situations that would limit compliance with study requirements
  • No known HIV infection or chronic hepatitis B or C infection
  • No serious, non-healing wound, active ulcer, or untreated bone fracture

    • Patients with fractures secondary to metastatic disease are eligible after appropriate radiotherapy
  • No significant traumatic injury within the past 4 weeks
  • No known or suspected allergy or hypersensitivity to any component of bevacizumab, sorafenib tosylate, or their excipients or to any other agent given in the course of this study
  • No malabsorption problem
  • None of the following within the past 6 months:

    • Significant vascular disease (e.g., aortic aneurysm or aortic dissection)
    • Peripheral arterial thrombosis
    • Symptomatic peripheral vascular disease
    • Abdominal fistula
    • Gastrointestinal perforation
    • Intra-abdominal abscess
  • No other active malignancy within the past 3 years except non melanoma skin cancer or carcinoma in situ of the cervix

    • Prior malignancy allowed provided patient is not receiving other specific treatment for that malignancy (other than hormonal therapy)
  • No other concurrent investigational agent for this cancer
  • Prior radiotherapy allowed
  • No prior sorafenib tosylate
  • No prior discontinuation of bevacizumab due to adverse events
  • More than 4 weeks since prior and no concurrent participation in any other experimental drug study
  • More than 4 weeks since prior St. John's wort or rifampin
  • More than 4 weeks since prior and no concurrent major surgical procedure or open biopsy
  • More than 7 days since prior core biopsy or minor surgical procedure, including placement of a vascular access device
  • No concurrent anticoagulant, except low-dose warfarin or heparin for deep venous thrombosis prophylaxis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00826540

  Show 211 Study Locations
Sponsors and Collaborators
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Axel Grothey, MD North Central Cancer Treatment Group

Layout table for additonal information
Responsible Party: Alliance for Clinical Trials in Oncology Identifier: NCT00826540     History of Changes
Other Study ID Numbers: NCCTG-N054C
NCI-2009-01177 ( Registry Identifier: CTRP (Clinical Trials Reporting System) )
U10CA025224 ( U.S. NIH Grant/Contract )
CDR0000632342 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: January 22, 2009    Key Record Dates
Results First Posted: March 3, 2014
Last Update Posted: September 6, 2017
Last Verified: August 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Rectal Neoplasms
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents, Immunological
Antibodies, Monoclonal
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Immunologic Factors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action